


LISTING OF CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the captioned application.

1-16. (Cancelled).

17. (New) A compound of formula (I),



the *N*-oxide forms, the addition salts and the stereo-chemically isomeric forms thereof, wherein *n* is 0, 1 or 2;

X is N or CR⁷, wherein R⁷ is hydrogen or taken together with R¹ may form a bivalent radical of formula -CH=CH-CH=CH-;

R¹ is C₁₋₆alkyl or thiophenyl;

R² is hydrogen, hydroxy, C₁₋₆alkyl, C₃₋₆alkynyl or taken together with R³ may form =O; except that when *X* is N, R² together with R³ cannot form =O;

R³ is a radical selected from



wherein

s is 0, 1, 2 or 3;

R⁸, R¹⁰ and R¹¹ are each independently selected from -CHO, C₁₋₆alkyl,

hydroxyc₁₋₆alkyl, C₁₋₆alkylcarbonyl, amino, C₁₋₆alkylamino,

di(C₁₋₆alkyl)aminoC₁₋₆alkyl, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylcarbonylaminoC₁₋₆alkyl,

piperidinylC₁₋₆alkylaminocarbonyl, piperidinyl, piperidinylC₁₋₆alkyl,

piperidinylC₁₋₆alkylaminocarbonyl, C₁₋₆alkyloxy, thiophenylC₁₋₆alkyl,
 pyrrolylC₁₋₆alkyl, arylC₁₋₆alkylpiperidinyl, arylcarbonylC₁₋₆alkyl, arylcarbonylpiperidinylC₁₋₆alkyl, haloindozolylpiperidinylC₁₋₆alkyl,
 arylC₁₋₆alkyl(C₁₋₆alkyl)aminoC₁₋₆alkyl, and

R⁹ is hydrogen or C₁₋₆alkyl;


or R³ is a group of formula




wherein

t is 0, 1, 2 or 3;


-Z is a heterocyclic ring system selected from




(c-1)




(c-3)




(c-5)




(c-6)




(c-7)




(c-8)



(c-9)




(c-10)



(c-11)

wherein R¹² is hydrogen, halo, C₁₋₆alkyl, aminocarbonyl, amino, hydroxy, aryl,



C₁₋₆alkylaminoC₁₋₆alkyloxy, C₁₋₆alkyloxyC₁₋₆alkyl, C₁₋₆alkyloxyC₁₋₆alkylamino, arylC₁₋₆alkyl,
 di(phenylC₂₋₆alkenyl), piperidinyl, piperidinylC₁₋₆alkyl,

C₃₋₁₀cycloalkyl, C₃₋₁₀cycloalkylC₁₋₆alkyl, aryloxy(hydroxy)C₁₋₆alkyl, haloindazolyl, arylC₁₋₆alkyl, arylC₂₋₆alkenyl, arylC₁₋₆alkylamino, morpholino, C₁₋₆alkylimidazolyl, pyridinylC₁₋₆alkylamino; and

R¹³ is hydrogen, piperidinyl or aryl;

R⁴, R⁵ and R⁶ are each independently selected from hydrogen, halo, trihalomethyl, trihalomethoxy, C₁₋₆alkyl, C₁₋₆alkyloxy, amino, aminoC₁₋₆alkyl, di(C₁₋₆alkyl)amino, di(C₁₋₆alkyl)aminoC₁₋₆alkyloxy or C₁₋₆alkyloxycarbonyl, or C₁₋₆alkyl substituted with 1, 2 or 3 substituents independently selected from hydroxy, C₁₋₆alkyloxy, or aminoC₁₋₆alkyloxy; or when R⁵ and R⁶ are on adjacent positions they may taken together form a bivalent radical of formula

-O-CH₂-O (d-1),

-O-(CH₂)₂-O- (d-2),

-CH=CH-CH=CH- (d-3), or

-NH-C(O)-NR¹⁴=CH- (d-4),

wherein R¹⁴ is C₁₋₆alkyl;

and aryl is phenyl, phenyl substituted with halo, C₁₋₆alkyl or C₁₋₆alkyloxy.

18. (New) A compound as claimed in claim 17 wherein

R¹ is C₁₋₆alkyl; R³ is a radical selected from (a-1), (a-2), (a-3) or (a-5) or is a group of formula (b-1); s is 0, 1 or 2; R⁸ and R¹⁰ are each independently selected from


-CHO, C₁₋₆alkyl, hydroxyC₁₋₆alkyl, di(C₁₋₆alkyl)aminoC₁₋₆alkyl,

C₁₋₆alkylcarbonylaminoC₁₋₆alkyl, piperidinylC₁₋₆alkyl,

piperidinylC₁₋₆alkylaminocarbonyl, C₁₋₆alkyloxy, thiophenylC₁₋₆alkyl,

pyrrolylC₁₋₆alkyl, arylC₁₋₆alkylpiperidinyl, arylcarbonylC₁₋₆alkyl, arylcarbonylpiperidinylC₁₋₆alkyl, haloindozolylpiperidinylC₁₋₆alkyl, or

arylC₁₋₆alkyl(C₁₋₆alkyl)aminoC₁₋₆alkyl; t is 0 or 2; -Z is a heterocyclic ring system selected from (c-1), (c-2), (c-4), (c-6), (c-8), (c-9), or (c-11); R¹² is hydrogen,



C₁₋₆alkyl, aminocarbonyl,

, C₁₋₆alkyloxyC₁₋₆alkylamino,

di(phenylC₂₋₆alkenyl), piperidinylC₁₋₆alkyl, C₃₋₁₀cycloalkyl,


C₃₋₁₀cycloalkylC₁₋₆alkyl, haloindazolyl, or arylC₂₋₆alkenyl; R⁴, R⁵ and R⁶ are each

independently selected from hydrogen, halo, trihalomethyl, trihalomethoxy,


C₁₋₆alkyl, C₁₋₆alkyloxy, di(C₁₋₆alkyl)amino, di(C₁₋₆alkyl)aminoC₁₋₆alkyloxy or

C₁₋₆alkyloxycarbonyl; and when R⁵ and R⁶ are on adjacent positions they may taken together form a bivalent radical of formula (d-1) or (d-2).


19. (New) A compound according to claim 17 wherein
 n is 0; X is CH; R¹ is C₁₋₆alkyl; R² is hydrogen; R³ is a group of formula (b-1); t is 2; -Z is a heterocyclic ring system selected from (c-1); R¹² is hydrogen; R¹³ is hydrogen; and R⁵ and R⁶ are on adjacent positions and taken together form a bivalent radical of formula (d-2).
20. (New) A compound selected from compounds No 16, compound No 144, and compound No. 145:



compound 16



Compound 144



Compound 145

21. (New) A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 17.
22. (New) A combination of a compound as claimed in Claim 17 with a chemotherapeutic agent.